EP Patent

EP3735222A1 — Liquid compositions of aprepitant

Assigned to FTF Pharma Pvt Ltd · Expires 2020-11-11 · 6y expired

What this patent protects

Liquid dosage forms of Aprepitant are not much explored. The present invention describes ready to use, oral liquid compositions of Aprepitant suitable for the patients having swallowing difficulties. The liquid compositions of the present invention are storage stable for prolonge…

USPTO Abstract

Liquid dosage forms of Aprepitant are not much explored. The present invention describes ready to use, oral liquid compositions of Aprepitant suitable for the patients having swallowing difficulties. The liquid compositions of the present invention are storage stable for prolonged time and can be used for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and for the prevention of postoperative nausea and vomiting.

Drugs covered by this patent

Patent Metadata

Patent number
EP3735222A1
Jurisdiction
EP
Classification
—
Expires
2020-11-11
Drug substance claim
No
Drug product claim
No
Assignee
FTF Pharma Pvt Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.